InnoCan Pharma (FRA:IP40) Cash per Share: €1.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IP40 InnoCan Pharma Corp FRA:IP40
58 GF Score
Price €1.50
GF Value €9.45
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is InnoCan Pharma Cash per Share?

InnoCan Pharma FRA:IP40 -23.66% 58 Cash per Share is €1.27 as of Mar. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €9.45 (Possible Value Trap). The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). InnoCan Pharma's Cash per Share for the quarter that ended in Mar. 2026 was €1.27.

InnoCan Pharma  (FRA:IP40) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

InnoCan Pharma Cash per Share Related Terms

InnoCan Pharma Cash per Share Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Cash per Share Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 2.56 1.22 0.86 1.07 1.27

InnoCan Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.31 1.40 1.38 1.27 1.27
FRA:IP40
58GF Score
InnoCan Pharma Corp FRA:IP40
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCan Pharma Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

InnoCan Pharma's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.711/4.50
=1.27

InnoCan Pharma's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=5.732/4.50
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €1.27 mean?
InnoCan Pharma (FRA:IP40) has a Cash per Share of €1.27 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for InnoCan Pharma and its competitors.
Is InnoCan Pharma's Cash per Share too high?
InnoCan Pharma's current Cash per Share is €1.27. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Cash per Share compare to PG and CL?
InnoCan Pharma's Cash per Share of €1.27 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Consumer Packaged Goods company?
A good Cash per Share depends on the Consumer Packaged Goods industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for InnoCan Pharma and its competitors. InnoCan Pharma's current Cash per Share is €1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.45, compared to a current price of €1.50 — trading 84.1% below its estimated fair value. The current Cash per Share is €1.27. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Cash per Share is €1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of €1.50 is trading 84.1% below its estimated GF Value™ of €9.45. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for FRA:IP40:

  • Cash per Share: €1.27
  • GF Value™: €9.45 vs. price of €1.50 (84.1% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score

Get the complete analysis for FRA:IP40

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price
€9.45
GF Value